Product Description: Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4+ and CD8+ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Diab A, et al. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. Clin Cancer Res. 2022 Jan 1;28(1):71-83.
CAS Number: 2128729-41-7
Molecular Weight: N/A
Compound Purity: 95.32
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others